Skip to main content

Table 1 Patient Characteristics, Tumor Survivin Expression, and CD4+ Survivin Specific Precursor Frequency

From: Survivin-specific CD4+ T cells are decreased in patients with survivin-positive myeloma

Age Disease Characteristics Durie Salmon Stage Prior Regimens Imid Therapy IMWG Response High Risk Survivin IHC* Survivin mRNA** Survivin Specific CD4+ Precursor Frequency (% of CD4)
67 IgG lambda IIB 1 yes VGPR no 7 - 0.000000
46 IgG lambda IIIA 1 no PR no - - 0.000000
69 IgG kappa IIA 1 yes PR no 8 - 0.000052
67   IIIA 2 yes   yes 5 1.375 0.000274
64 IgG kappa IA 2 no VGPR yes 5 - 0.000346
49 IgG lambda IIIB 1 yes VGPR no - - 0.000349
56 IgG kappa IIIB 2 no PR no 7 1.248 0.000401
46 IgA kappa IA 2 no PR no 4 0.814 0.000466
57 IgG kappa IIIB 2 yes PR no 6 0.625 0.000643
69 IgG kappa IIIA 1 yes PR yes - - 0.000798
69 IgG kappa IA 1 no VGPR no - - 0.001007
62 IgG lambda IIIA 1 no PR no - - 0.001195
66 IgG kappa IA 2 no PR yes 4 0.481 0.001579
74 IgA lambda IIIB 2 yes PR yes 2 0.226 0.002250
62 IgG kappa IIIA 1 yes VGPR yes 5 - 0.002657
50 lambda light chain IIA 1 no VGPR no - - 0.006804
  1. *Survivin IHC of bone marrow plasma cells by the Allred scoring system. **Survivin mRNA of isolated CD138+ marrow cells normalized to GAPDH.